SCHEMBL462976

SCHEMBL462976

Brc1n[nH]c2cccc(-c3cnc4ccccc4c3)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 3/20 0.51
▸ PDGFRA P16234 3/20 0.51
▸ BIRC5 O15392 1/20 0.49
▸ NISCH Q9Y2I1 1/20 0.43
▸ LRRK2 Q5S007 1/20 0.42
▸ PLK4 O00444 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ LYN P07948 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ RPS6KB1 P23443 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ MARK3 P27448 1/20 0.41
▸ AKT1 P31749 1/20 0.41
▸ AKT2 P31751 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL461745 0.84 PDGFRB (0.51) PDGFRBPDGFRABIRC5NISCHLRRK2
SCHEMBL462907 0.84 PDGFRA (0.51) PDGFRBPDGFRABIRC5NISCHLRRK2
SCHEMBL462861 0.81 PDGFRB (0.48) PDGFRBPDGFRABIRC5NISCHLRRK2
SCHEMBL2182815 0.76 PDGFRB (0.60) PDGFRBPDGFRABIRC5NISCHPIM1
SCHEMBL1394258 0.74 METAP2 (0.60) PDGFRBPDGFRABIRC5NISCHAURKA
SCHEMBL1042969 0.74 PDGFRA (0.51) PDGFRBPDGFRABIRC5NISCHKDR
SCHEMBL1045276 0.74 PDGFRB (0.61) PDGFRBPDGFRABIRC5NISCHPIM1
SCHEMBL17179205 0.72 PIM1 (0.60) PDGFRBPDGFRABIRC5NISCHLRRK2
SCHEMBL2198777 0.70 PDGFRB (0.60) PDGFRBPDGFRABIRC5NISCHCYP2A6
SCHEMBL30547072 0.70 PDGFRB (0.60) PDGFRBPDGFRABIRC5NISCHCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408762-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-25 — — EP disclosed
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-12 — — US disclosed
WO-2010106290-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 PDGFRB 1416/4885PDGFRA 1508/4885BIRC5 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback